Home > Cardiology > AHA 2019 > Trials in Electrophysiology and Left Ventricular Function > Carvedilol does not improve exercise performance in Fontan patients

Carvedilol does not improve exercise performance in Fontan patients

Presented By
Dr Ryan Butts, University of Texas Southwestern, Dallas, USA
Conference
AHA 2019
Dr Ryan Butts (University of Texas Southwestern, Dallas, USA) presented the results of a double-blind, placebo-controlled, cross-over trial of carvedilol in single-ventricle patients with Fontan physiology [1]. The rationale behind the trial was that beta-blockers may ameliorate the increased circulating catecholamines in these patients and, consequently, improve their exercise performance; however, no difference was observed between the 2 arms. The study enrolled 26 single-ventricle patients between 10-35 years old with a previous Fontan operation who were able to complete a maximal exercise test (respiratory exchange ratio [RER] >1.0). Two 12-week treatment arms were separated by a period of 6 weeks for drug washout. Exercise testing was performed at the beginning and end of each treatment arm. Study drug was increased to a goal maximum dose (0.2-0.3 mg/kg/dose twice daily). The primary study outcome was an improvement in peak oxygen consumption/kg (p...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on